OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
June 26, 2024
A retrospective study investigates whether use of these portals can be defined by clinical and sociodemographic data.
The latest news for pharma industry insiders.
June 25, 2024
The Hopewell facility—which will serve as the CDMO’s North American hub—is expected to help accelerate the cell and gene therapy delivery process.
The company acquires Alimera Sciences for $381 million upfront, while establishing its interest in ophthalmology.
June 24, 2024
A study examines the economical validity of using this therapy as a treatment for unresectable stage III non–small cell lung cancer.
In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses ways that changes made to reimbursement models are affecting patient therapies in the biosimilar space.
June 21, 2024
The partnership will offer an end-to-end manufacturing solution for biopharma companies.
Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.